The ReNEW study for dry AMD is evaluating the efficacy, safety, and pharmacokinetics of daily subcutaneous injections of ...

Macular degeneration, particularly age-related macular degeneration, is a leading cause of vision loss worldwide.  This ...

Zervimesine is an investigational oral, once-daily pill being developed for the treatment of CNS diseases, including ...

Meanwhile, individuals who began with better baseline vision saw smaller, yet still clinically relevant, improvements that counteracted the natural decline expected in dry AMD progression.

New research shows that eating this tasty snack daily can help protect against the leading cause of vision loss in older ...

Avirmax Biopharma Inc. has begun IND-enabling studies of ABI-201, a gene therapy for dry age-related macular degeneration ...

Around 1 in 200 people has AMD at 60 however by the age of 90 this rises to 1 in 5. For Ruth Reddock, her diagnosis of Dry Age-Related Macular Degeneration (AMD) in 2022 led to an NHS Trust ...

a separate analysis of these CSF samples to identify pathways associated with dry AMD that were altered by treatment with zervimesine; c) an in vitro study conducted in collaboration with ...

Age-related macular degeneration (AMD) AMD is a common eye condition that happens as you get older. It affects the macula, ...

For anyone looking to tackle high humidity levels and poor air circulation, I would absolutely recommend the MeacoDry Arete ...

Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing neurodegenerative disease candidates, (the "Company" or "Cognition") ...

When 92-year-old Derek Priest started to lose the vision in his one good eye, it was thanks to the expertise and diligence of ...